What is the appropriate enoxaparin (Lovenox) dosing for a 60‑kg patient with a creatinine clearance of 28 mL/min for treatment of deep‑vein thrombosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Enoxaparin Dosing for DVT Treatment in a 60 kg Patient with CrCl 28 mL/min

For this 60 kg patient with severe renal impairment (CrCl 28 mL/min), the appropriate enoxaparin dose for DVT treatment is 60 mg subcutaneously once daily (1 mg/kg every 24 hours).

Dosing Algorithm

The FDA-approved dosing for severe renal impairment is clear and takes precedence 1:

  • Standard therapeutic dosing: 1 mg/kg every 12 hours
  • Severe renal impairment (CrCl <30 mL/min): 1 mg/kg every 24 hours
  • For this 60 kg patient: 60 mg subcutaneously once daily

This dose reduction from twice-daily to once-daily dosing is mandatory, not optional, when CrCl falls below 30 mL/min 1.

Supporting Evidence

The most recent ACC/AHA guidelines 2, 3 and ASCO cancer-associated thrombosis guidelines 4 all specify dose reduction to once-daily dosing when CrCl <30 mL/min. The 2025 ACC/AHA guideline explicitly states: "Reduce dose to 1 mg/kg per d subcutaneous if CrCl <30 mL/min" 3.

Critical consideration: At CrCl 28 mL/min, this patient sits just below the 30 mL/min threshold. Some clinicians might consider 1 mg/kg every 12 hours given the proximity to 30 mL/min, but the FDA label is unambiguous—once CrCl drops below 30 mL/min, once-daily dosing is required 1.

Monitoring Recommendations

While routine coagulation monitoring is not required for standard enoxaparin dosing, anti-Xa level monitoring should be strongly considered in this patient 1:

  • Target anti-Xa level: 0.6-1.0 IU/mL for therapeutic anticoagulation
  • Timing: Measure 4 hours after the third dose
  • Adjust dosing if levels fall outside therapeutic range

Research evidence supports this approach—studies demonstrate that renal function is the primary determinant of enoxaparin clearance, and dose adjustments based on anti-Xa levels successfully maintain therapeutic anticoagulation while minimizing bleeding risk in renally impaired patients 5, 6, 7.

Common Pitfalls to Avoid

  1. Do not use twice-daily dosing at this CrCl level—this significantly increases bleeding risk due to drug accumulation
  2. Do not round up to 40 mg thinking it's "close enough"—use the full weight-based calculation (60 mg for 60 kg)
  3. Do not use fondaparinux as an alternative—it is contraindicated when CrCl <30 mL/min 3, 1
  4. Monitor for bleeding complications more vigilantly than in patients with normal renal function

Transition to Oral Anticoagulation

Continue enoxaparin for minimum 5 days and until INR 2.0-3.0 if transitioning to warfarin 1. Consider direct oral anticoagulants with caution—edoxaban requires dose reduction to 30 mg daily in patients ≤60 kg OR CrCl 30-50 mL/min 4.

References

Related Questions

Should a patient with a creatinine clearance of 40 mL/min receive enoxaparin (Lovenox) 40 mg subcutaneously once daily for prophylaxis?
What are the recommended dosing and monitoring guidelines for enoxaparin for deep vein thrombosis prophylaxis and clopidogrel for cardiac protection?
How should enoxaparin be dosed in a 60‑kg patient with a creatinine clearance of 70 mL/min?
What enoxaparin (Clexane) dosing regimen is appropriate for a ~60 kg patient needing therapeutic anticoagulation, and how should it be adjusted in severe renal impairment (creatinine clearance <30 mL/min)?
In a patient with creatinine clearance less than 30 mL/min, should the enoxaparin dose be 0.5 mg/kg?
Is it safe to apply a heating pad to a limb with an acute deep vein thrombosis (DVT)?
What is the most likely etiology and appropriate diagnostic and therapeutic approach for a patient presenting with sensorineural hearing loss and myositis?
What neuro‑monitoring is routinely used in Canadian cardiac operating rooms, and would the perfusionist or surgeon be expected to comment if they suspect a problem?
How should enoxaparin be dosed in a 60‑kg patient with a creatinine clearance of 70 mL/min?
During valve repair surgery at a cardiac operating room, are additional cerebral monitoring modalities used besides near‑infrared spectroscopy (NIRS) if the NIRS sensor fails intraoperatively?
Is it standard practice in Canada to have an alternative cerebral monitoring modality available if near-infrared spectroscopy (NIRS) fails?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.